{"mainPropery":{"diseaseId":7368,"diseaseName":"Peripheral T-cell lymphoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7368/peripheral-t-cell-lymphoma","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"UMLS","identifierId":"C0079774"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[],"resource descriptions":[{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Peripheral+T-cell+lymphoma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Peripheral T-cell lymphoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:0050749' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/non-hodgkin-s-lymphoma' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":11973,"relatedDiseaseName":"Angioimmunoblastic T-cell lymphoma","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":11955,"relatedDiseaseName":"Lymphoma","relation":"Parent","isRare":false,"hasGardPage":false}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":536,"genericName":"Brentuximub vedotin","tradeName":"Adcetris","tradeLink":"https://adcetris.com/","manufacturer":"","sponsor":"Seattle Genetics, Inc","indication":"November 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone. In November 2016, it was approved for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma. In August 2011, it was approved for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/adcetris","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a611052.html"},{"productId":606,"genericName":"Belinostat","tradeName":"Beleodaq","tradeLink":"http://www.sppirx.com/322-spectrum-products-late-stage-beleodaq.html","manufacturer":"","sponsor":"Spectrum Pharmaceuticals, Inc.","indication":"July 2014, belinostat (Beleodaq) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/866323-14-0","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614035.html"},{"productId":502,"genericName":"Pralatrexate","tradeName":"Folotyn","tradeLink":"http://folotyn.com/","manufacturer":"","sponsor":"Allos Therapeutics, Inc.","indication":"September 2009, pralatrexate (Folotyn) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/folotyn","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a610001.html"}],"EncodedName":"Peripheral_T-cell_lymphoma"}